We provide you with 20 years of free, institutional-grade data for AKRO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AKRO. Explore the full financial landscape of AKRO stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-08 | 1744659 | AKRO | 10-Q | Url |
| 2025-05-12 | 1744659 | AKRO | 10-Q | Url |
| 2025-02-28 | 1744659 | AKRO | 10-K | Url |
| 2024-11-08 | 1744659 | AKRO | 10-Q | Url |
| 2024-08-09 | 1744659 | AKRO | 10-Q | Url |
| 2024-05-10 | 1744659 | AKRO | 10-Q | Url |
| 2024-02-29 | 1744659 | AKRO | 10-K | Url |
| 2023-11-13 | 1744659 | AKRO | 10-Q | Url |
| 2023-08-11 | 1744659 | AKRO | 10-Q | Url |
| 2023-05-15 | 1744659 | AKRO | 10-Q | Url |
| 2023-03-17 | 1744659 | AKRO | 10-K | Url |
| 2022-11-04 | 1744659 | AKRO | 10-Q | Url |
| 2022-08-05 | 1744659 | AKRO | 10-Q | Url |
| 2022-05-06 | 1744659 | AKRO | 10-Q | Url |
| 2022-02-25 | 1744659 | AKRO | 10-K | Url |
| 2021-11-12 | 1744659 | AKRO | 10-Q | Url |
| 2021-08-13 | 1744659 | AKRO | 10-Q | Url |
| 2021-05-13 | 1744659 | AKRO | 10-Q | Url |
| 2021-03-16 | 1744659 | AKRO | 10-K | Url |
| 2020-11-12 | 1744659 | AKRO | 10-Q | Url |
| 2020-08-12 | 1744659 | AKRO | 10-Q | Url |
| 2020-07-06 | 1744659 | AKRO | S-1 | Url |
| 2020-05-13 | 1744659 | AKRO | 10-Q | Url |
| 2020-03-16 | 1744659 | AKRO | 10-K | Url |
| 2019-11-12 | 1744659 | AKRO | 10-Q | Url |
| 2019-08-12 | 1744659 | AKRO | 10-Q | Url |
| 2019-05-24 | 1744659 | AKRO | S-1 | Url |
Akero Therapeutics, Inc(NASDAQ:AKRO) 
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protec...
Website: http://www.akerotx.com
Founded: 2017
IPO Price: $16 (Jun 20, 2019)
Full Time Employees: 16
CEO: Andrew Cheng
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about AKRO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.